Clinical trial · Expanded Access

Standardization Research of TCM Syndrome Differentiation and Treatment on Advanced Breast Cancer

NCT02011880CI-TRIAL-00012984temporarily not availableClinicalTrials.gov clinicaltrialsPublishedExplore in graph →

Summary

Brief summary (as posted)

The purpose of this clinical research study is to learn if the clinical effects of combined Chinese herbal medicine with endocrine therapy is better than endocrine therapy alone in improving the quality of life and shrinking and slowing the growth of the cancer in women with breast cancer bone metastasis.

Conditions

Conditions (2)

Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.

Condition (as posted)	Mapped entity	Match	Confidence
Bone Metastasis	Breast Neoplasm	PROBABILISTIC	0.70
Breast Cancer	Malignant Breast Neoplasm	CURATED_EXACT	0.92

Interventions

Interventions (1)

Intervention	Type	Mapped drug	Match
Chinese Herbs	Dietary Supplement	—	UNRESOLVED

Eligibility

Eligibility (as posted)

Sex: Female
Minimum age: 20 Years
Maximum age: 70 Years

Show eligibility criteria text

Inclusion Criteria:

* Histologically confirmed breast cancer and hormone receptor positive.
* Bone metastasis and have a measurable foci.
* TCM syndrome type is deficiency of both vital energy and Yin ;maladjustment of ChongRen with deficiency Yang syndrome.
* The Karnofsky score ≥60.
* VAS score ≥3.
* Expected survival at least 6 months or greater.
* Age between 20 to 70(include 20 and 70).
* The function of cardiovascular,hepar,renal and hematopoieses is relatively normal.

Exclusion Criteria:

* Women during the pregnancy or breast feeding.
* With a cardiovascular,hepar,renal,hematopoieses or other serious complications.
* Be allergic to the trial drugs.
* Participating in other trials.

References

Publications (0)

Data not yet available

No reference posted for this study.